Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

Now Viewing

EP: 1.Navigating Beyond FOLFOX/FOLFIRI: Key Therapies in Advanced mCRC

EP: 2.Real-World Impact of SUNLIGHT Outcomes in mCRC

EP: 3.Fruquintinib in mCRC: Key Insights From FRESCO-2

EP: 4.Comparing mCRC Therapies: FTD/TPI Plus Bevacizumab, Fruquintinib, and Regorafenib

EP: 5.Optimizing mCRC Therapy Sequencing: Key Considerations and Future Directions

EP: 6.Guiding Patients Through Third-Line mCRC Therapy Decisions

EP: 7.Navigating Toxicity: Comparing Third-Line mCRC Therapies

EP: 8.Evaluating Quality of Life and Adherence With mCRC Treatment Options

EP: 9.Integrating Support Services and Caregiver Roles in mCRC Care

EP: 10.mCRC Treatment Access: IRA Cost Cap Impact and Final Insights

Provide a brief overview of our therapy options in metastatic colorectal cancer that has progressed after FOLFOX/FOLFIRI.

• Discuss the importance of biomarker screening.
• A majority of patients will not have targetable biomarkers, so provide emphasis on the 3 therapies: regorafenib, FTD/TPI plus or minus bevacizumab, and fruquintinib.